|
Video: What is a Stock Split?
|
|
CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells. According to our CRISPR Therapeutics AG stock split history records, CRISPR Therapeutics AG has had 0 splits. | |
|
CRISPR Therapeutics AG (CRSP) has 0 splits in our CRISPR Therapeutics AG stock split history database.
Looking at the CRISPR Therapeutics AG stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CRISPR Therapeutics AG shares, starting with a $10,000 purchase of CRSP, presented on a split-history-adjusted basis factoring in the complete CRISPR Therapeutics AG stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/20/2016 |
|
End date: |
05/07/2024 |
|
Start price/share: |
$13.94 |
|
End price/share: |
$55.53 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
298.35% |
|
Average Annual Total Return: |
20.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$39,841.08 |
|
Years: |
7.55 |
|
|
|
|
|